Celcuity reports Q3 2026 earnings with zero revenue and commercial launch of Revtopik
Celcuity posted no revenue for the third quarter of 2026 and recorded a GAAP loss of $73.34 million, resulting in a GAAP EPS of ($1.33). The company reported Non‑GAAP EPS of ($1.21), beating estimates by $0.32, while operating cash flow was ($66.2 million). It launched its breast‑cancer drug Revtopik on September 30, and said that orders have been placed by 78% of the 36 largest strategic accounts, with 91% of U.S. commercial and Medicare lives now covered by payer plans.
Why it matters
The company’s cash balance of $642.7 million is expected to fund operations through 2029, but the lack of revenue and ongoing cash burn highlight the need for commercial uptake. Management estimates a $9 billion annual addressable market for Revtopik, which could drive future growth if adoption materializes.
Key facts
- 1Celcuity reported zero revenue in Q3 2026. tradingview.com
- 2GAAP net loss was $73.34 million, giving GAAP EPS of ($1.33). tradingview.com
- 3Non‑GAAP EPS was ($1.21), beating estimates by $0.32. seekingalpha.com
- 4Operating cash flow was ($66.2 million). seekingalpha.com
- 5Operating expenses rose to $77.3 million. finance.yahoo.com
- 6Cash on hand at quarter end was $642.7 million. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.